Developer docs
API playgroundTry for free, no card

Search company profiles

Corcym

Full company profile

uuid0006qxl

Namestring
Corcym
Legal namestring
Corcym S.r.l.
Websiteurl
corcym.com
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
heart valve prostheses, surgical heart devices, structural heart disease, cardiac surgery equipment, annuloplasty repair devices
Industry2 codes
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Cardiovascular Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Corcym generates revenue through the sale of surgical heart valve prostheses, repair devices, and minimally invasive cardiac surgery instruments. The company offers a comprehensive portfolio including sutureless valves, mechanical valves, annuloplasty rings, and related surgical instruments to cardiac surgeons and hospitals worldwide.

corcym.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Perceval Platform
Description

Sutureless surgical aortic valve platform for aortic valve replacement

corcym.com
+5 more records
Core offering1 text field

Corcym designs, manufactures, and sells surgical solutions for structural heart disease, including sutureless aortic valves (Perceval Platform and Perceval Plus LANCELOT), mechanical aortic valves, mitral and aortic annuloplasty repair devices (Memo 4D and HAART), and minimally invasive cardiac surgery instruments (Miami Instruments). The company also provides a CT scan reading service using 3mensio software for pre-operative planning and a professional education program (Corcym Academy) for cardiac surgeons.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 75,000+ patients implanted with 13 years of clinical results demonstrating excellent outcomes
+2 more records
Product overview1 text field

Corcym is a global medical device company offering a comprehensive portfolio of surgical solutions for structural heart disease. The product portfolio centers on the Perceval Platform — the only truly sutureless surgical aortic valve available — alongside mechanical aortic valve replacements, the Memo 4D mitral annuloplasty ring, and HAART aortic annuloplasty devices for repair. The company also provides Miami Instruments for minimally invasive cardiac surgery, a CT scan reading service using 3mensio software for pre-operative planning, and Corcym Academy for professional surgeon education. Supporting services include a device tracking system for regulatory compliance and an Investigator Initiated Research program. The portfolio spans aortic and mitral/tricuspid repair and replacement solutions, with clinical evidence supported by studies including MANTRA.

Product and service7 records
1Perceval Sutureless Aortic Heart Valve Platform
CategoryAortic Valve Replacement Devices
Description

Sutureless aortic valve platform featuring a collapsible biological valve design that simplifies surgical implantation, reduces surgical impact, and facilitates faster patient recovery. The only truly sutureless surgical valve available on the market, with the next-generation Perceval Plus LANCELOT featuring precision laser-cut bovine pericardial leaflets. Used by cardiac surgeons in aortic valve replacement procedures in hospitals worldwide.

2HAART Aortic Annuloplasty Devices
CategoryAortic Valve Repair Devices
Description

Aortic annuloplasty devices designed for aortic valve repair, with dedicated sessions available for trileaflet, bileaflet, and congenital pathologies. Used by cardiac surgeons for aortic valve repair procedures.

3Memo 4D Mitral Annuloplasty Ring
4Mechanical Aortic Valves
5Miami Instruments for Minimally Invasive Cardiac Surgery
6CT Scan Reading Service
7Corcym Academy Professional Education Program
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Edwards Lifesciences is the global leader in structural heart disease, with the leading TAVR franchise (SAPIEN) and surgical valve portfolio. It is the most important competitor Corcym faces in aortic valve replacement and the reference point for the structural heart market in which Corcym operates.

TypeBroad incumbent
Description

Medtronic offers a broad cardiovascular portfolio including surgical heart valves, TAVR (Evolut), and cardiac surgery devices. Its scale, global sales force, and full structural heart offering make it a direct competitor across Corcym's surgical valve and repair categories.

3Abbott
TypeBroad incumbent
Description

Abbott competes in structural heart through its Tendyne TMVR system and other cardiovascular devices, plus it has a large hospital sales channel. Its growing presence in structural heart overlaps directly with Corcym's target market of cardiac surgeons and hospitals.

TypeDirect peer
Description

LivaNova PLC was the parent of the heart valve business from which Corcym was carved out in 2021. While LivaNova has since divested this segment, it shares deep operational, clinical, and product heritage with Corcym and represents the most direct historical predecessor in surgical heart valves.

TypeDirect peer
Description

Artivion (formerly CryoLife) is a specialist in tissue heart valves (including the On-X mechanical valve) and cardiac repair products. It is a direct competitor in surgical heart valve replacement and repair, serving the same cardiac surgery customer base as Corcym.

TypeBroad incumbent
Description

Boston Scientific has a growing cardiovascular and structural heart presence (including the ACURATE TAVR platform acquired from Symetis). Its global hospital sales force and broad device portfolio position it as a structural heart incumbent competing with Corcym for hospital contracts.

TypeEmerging player
Description

JenaValve is an emerging structural heart company developing transcatheter aortic valve repair devices (Align JAV) for aortic regurgitation. It competes in the broader structural heart disease market and represents a next-generation entrant in the same therapeutic area as Corcym.

8MicroPort Scientific
TypeEmerging player
Description

MicroPort has a cardiovascular franchise in emerging markets including heart valves and interventional cardiology devices. Its strong Asia-Pacific presence and surgical valve portfolio make it a peer in the structural heart surgery category, with overlap in growth markets.

TypeRegional player
Description

Meril Life Sciences is an India-based medical device company with a structural heart valve portfolio (including the MyVal TAVR and surgical valves). It is a regional competitor to Corcym in emerging markets, with comparable surgical heart valve products.

TypeOthers
Description

AtriCure is a cardiac surgery company focused on atrial fibrillation and left atrial appendage management, serving the same cardiac surgeon customer base as Corcym. While not a direct valve competitor, it is an adjacent specialty device company that competes for hospital capital and surgeon attention.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corcym

Cardiovascular Medical Devicescorcym.com

Corcym firmographics

Firmographics
Name
Corcym
Legal name
Corcym S.r.l.
Website
https://corcym.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Corcym industry classification

Industry
Product category
Cardiovascular Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAFAB
Structural Heart Valves (TAVR/SAVR) & Valve Repair
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAH
Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Heart valve prostheses
  • Surgical heart devices
  • Structural heart disease
  • Cardiac surgery equipment
  • Annuloplasty repair devices

Where Corcym is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices4 records

Markets served

Corcym business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales: Corcym generates revenue through the sale of surgical heart valve prostheses, repair devices, and minimally invasive cardiac surgery instruments. The company offers a comprehensive portfolio including sutureless valves, mechanical valves, annuloplasty rings, and related surgical instruments to cardiac surgeons and hospitals worldwide.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Corcym product offering

Product offering

Core offering

Corcym designs, manufactures, and sells surgical solutions for structural heart disease, including sutureless aortic valves (Perceval Platform and Perceval Plus LANCELOT), mechanical aortic valves, mitral and aortic annuloplasty repair devices (Memo 4D and HAART), and minimally invasive cardiac surgery instruments (Miami Instruments). The company also provides a CT scan reading service using 3mensio software for pre-operative planning and a professional education program (Corcym Academy) for cardiac surgeons.

Product overview

Corcym is a global medical device company offering a comprehensive portfolio of surgical solutions for structural heart disease. The product portfolio centers on the Perceval Platform — the only truly sutureless surgical aortic valve available — alongside mechanical aortic valve replacements, the Memo 4D mitral annuloplasty ring, and HAART aortic annuloplasty devices for repair. The company also provides Miami Instruments for minimally invasive cardiac surgery, a CT scan reading service using 3mensio software for pre-operative planning, and Corcym Academy for professional surgeon education. Supporting services include a device tracking system for regulatory compliance and an Investigator Initiated Research program. The portfolio spans aortic and mitral/tricuspid repair and replacement solutions, with clinical evidence supported by studies including MANTRA.

Differentiator

Problem solved

Functional benefit

Brands

  • Perceval Platform: Sutureless surgical aortic valve platform for aortic valve replacement
  • Memo 4D
  • HAART
  • Corcym Academy
  • MANTRA Study
  • Corcym Device Tracking System

Products and services

  • Perceval Sutureless Aortic Heart Valve Platform Sutureless aortic valve platform featuring a collapsible biological valve design that simplifies surgical implantation, reduces surgical impact, and facilitates faster patient recovery. The only truly sutureless surgical valve available on the market, with the next-generation Perceval Plus LANCELOT featuring precision laser-cut bovine pericardial leaflets. Used by cardiac surgeons in aortic valve replacement procedures in hospitals worldwide.
  • HAART Aortic Annuloplasty Devices Aortic annuloplasty devices designed for aortic valve repair, with dedicated sessions available for trileaflet, bileaflet, and congenital pathologies. Used by cardiac surgeons for aortic valve repair procedures.
  • Memo 4D Mitral Annuloplasty Ring
  • Mechanical Aortic Valves
  • Miami Instruments for Minimally Invasive Cardiac Surgery
  • CT Scan Reading Service
  • Corcym Academy Professional Education Program

Quantifiable outcome

  • 75,000+ patients implanted with 13 years of clinical results demonstrating excellent outcomes
  • +2 more outcomes

Companies that use Corcym

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Corcym technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Corcym partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Corcym competitors and assessment

Company assessment

Broad incumbents

  • Edwards Lifesciences: Edwards Lifesciences is the global leader in structural heart disease, with the leading TAVR franchise (SAPIEN) and surgical valve portfolio. It is the most important competitor Corcym faces in aortic valve replacement and the reference point for the structural heart market in which Corcym operates.
  • Medtronic: Medtronic offers a broad cardiovascular portfolio including surgical heart valves, TAVR (Evolut), and cardiac surgery devices. Its scale, global sales force, and full structural heart offering make it a direct competitor across Corcym's surgical valve and repair categories.
  • Abbott: Abbott competes in structural heart through its Tendyne TMVR system and other cardiovascular devices, plus it has a large hospital sales channel. Its growing presence in structural heart overlaps directly with Corcym's target market of cardiac surgeons and hospitals.
  • Boston Scientific: Boston Scientific has a growing cardiovascular and structural heart presence (including the ACURATE TAVR platform acquired from Symetis). Its global hospital sales force and broad device portfolio position it as a structural heart incumbent competing with Corcym for hospital contracts.

Direct peers

  • LivaNova: LivaNova PLC was the parent of the heart valve business from which Corcym was carved out in 2021. While LivaNova has since divested this segment, it shares deep operational, clinical, and product heritage with Corcym and represents the most direct historical predecessor in surgical heart valves.
  • Artivion: Artivion (formerly CryoLife) is a specialist in tissue heart valves (including the On-X mechanical valve) and cardiac repair products. It is a direct competitor in surgical heart valve replacement and repair, serving the same cardiac surgery customer base as Corcym.

Emerging players

  • JenaValve Technology: JenaValve is an emerging structural heart company developing transcatheter aortic valve repair devices (Align JAV) for aortic regurgitation. It competes in the broader structural heart disease market and represents a next-generation entrant in the same therapeutic area as Corcym.
  • MicroPort Scientific: MicroPort has a cardiovascular franchise in emerging markets including heart valves and interventional cardiology devices. Its strong Asia-Pacific presence and surgical valve portfolio make it a peer in the structural heart surgery category, with overlap in growth markets.

Regional players

  • Meril Life Sciences: Meril Life Sciences is an India-based medical device company with a structural heart valve portfolio (including the MyVal TAVR and surgical valves). It is a regional competitor to Corcym in emerging markets, with comparable surgical heart valve products.

Others

  • AtriCure: AtriCure is a cardiac surgery company focused on atrial fibrillation and left atrial appendage management, serving the same cardiac surgeon customer base as Corcym. While not a direct valve competitor, it is an adjacent specialty device company that competes for hospital capital and surgeon attention.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Corcym social profiles

Digital presence

Corcym compliance and trust

Trust signal

Compliance3 records

Corcym financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corcym leadership team

Management profile

Number of profiles

Profiles15 records

Corcym subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Corcym funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corcym M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corcym

What does Corcym do?

Corcym designs, manufactures, and sells surgical solutions for structural heart disease, including sutureless aortic valves (Perceval Platform and Perceval Plus LANCELOT), mechanical aortic valves, mitral and aortic annuloplasty repair devices (Memo 4D and HAART), and minimally invasive cardiac surgery instruments (Miami Instruments). The company also provides a CT scan reading service using 3mensio software for pre-operative planning and a professional education program (Corcym Academy) for cardiac surgeons.

Is Corcym a public or private company?

Corcym is a private company. It is classified as private equity controlled and is currently operating.

When was Corcym founded?

Corcym was founded in 2021. It employs 251 to 500 people.

Where is Corcym based?

Corcym is headquartered in London, United Kingdom, in the Europe region.

How does Corcym make money?

One revenue line is on record: medical Device Sales.

Who are Corcym's main competitors?

Broad incumbents on record are Edwards Lifesciences, Medtronic, Abbott and Boston Scientific. Direct peers are LivaNova and Artivion. Emerging players are JenaValve Technology and MicroPort Scientific. Meril Life Sciences is listed as a regional player. AtriCure is listed as an others.

Does Corcym have an API?

No public API is recorded for Corcym.

What industry is Corcym in?

Corcym's product category is Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAH, Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Medical Device NetworkNew study touts positive long-term data for Corcym’s sutureless aortic valveA new study of Corcym's Perceval Plus sutureless aortic valve reports cardiovascular benefit at seven-year follow-up. The findings come from the company's ongoing clinical follow-up study. The study highlights long-term positive outcomes for the valve.Business Wire BlogPositive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-upCorcym presented positive mid-term data on its Perceval Plus sutureless aortic valve at EACTS, including a sub-analysis of 708 patients with up to 7-year follow-up. The data showed 99.7% freedom from structural valve deterioration and 96.6% freedom from reoperation from 4 to 7 years. The company also launched TriMemo and Memo 4D Curve devices at the meeting.FinancialContent Business PagePositive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-upCorcym presented positive mid-term data on its Perceval Plus sutureless aortic valve from a sub-analysis of the MANTRA trial at EACTS. The study of 708 patients showed 99.7% freedom from structural valve deterioration from 3 to 7 years and 96.6% freedom from reoperation from 4 to 7 years. The data also reported quality-of-life improvements and low reintervention rates.Business Wire BlogCorcym Announces First-in-Human Implant of TriMemo®, Extending Its Memo Platform to Tricuspid Valve RepairCorcym announced the first-in-human implantation of TriMemo, a semi-rigid annuloplasty ring for tricuspid valve repair, performed at Cleveland Clinic. The FDA-cleared device, based on Corcym's Memo platform, received clearance in April 2026 and is commercially available in the U.S. Corcym will introduce it internationally at EACTS in October 2026.EIN PresswireInfluential Women Highlights Alicia Pate, PhD, PA-C: Physician Assistant and Senior Account ExecutiveAlicia Pate, a certified physician assistant with over 15 years in cardiology and cardiac surgery, serves as Senior Account Executive at CORCYM and Principal Perceval Clinical Trainer. She holds multiple advanced degrees and is a Fellow of the Association of Physician Assistants in Cardiovascular Surgery. She advocates for women in healthcare and emphasizes education and mentorship.Cardiovascular BusinessFDA-approved surgical aortic valve implanted for first time in USSurgeons at CHI Health successfully performed the first U.S. implantation of Corcym's FDA-approved Perceval Plus LANCELOT surgical aortic valve in September 2025. The device, which received regulatory approval in May 2025, features updated design elements including laser-cut leaflets and a zero-pressure fixation process intended to improve surgical consistency and patient recovery.PR NewswireFIRST U.S. IMPLANTATION OF NEXT-GENERATION PERCEVAL PLUS® LANCELOT VALVEA patient in the United States has become the first in the country to receive Corcym's next-generation Perceval Plus® LANCELOT sutureless aortic valve, with the procedure performed in September 2025 by a cardiac surgery team at CHI Health. The new valve features precision laser-cut bovine pericardial leaflets and builds on Corcym's established Perceval platform, which has been used worldwide for almost 20 years. The patient has recovered and returned to everyday activities following the implantation.Business Wire BlogCorcym Announces First-In-Human Implant of Memo 4D Curve™, Expanding Its Memo Mitral Repair PlatformCorcym announced the first-in-human implant of Memo 4D Curve, a semi-rigid open-configuration annuloplasty ring for mitral valve repair, performed by Dr. Michael Ibrahim at UVA Health. The FDA-cleared device is available in sizes up to 42 mm and expands the Memo platform to open configurations. Corcym will introduce it internationally at EACTS in October 2026.PR NewswireFIRST HEART VALVE REPLACEMENT USING NEW ROBOTIC SURGERY TECH AND ARTIFICIAL VALVE DESIGNED BY CORCYMCorcym announced that its Perceval Plus sutureless aortic heart valve was successfully used in the first-ever robotic aortic valve replacement procedure, performed at Cleveland Clinic through a small neck incision. The procedure combined Corcym's artificial heart valve with CardioPrecision's CoreVista Robot Enabling Platform in an AVATAR procedure. The CEO of Corcym stated this milestone strengthens the company's foothold in robotic surgery, while the surgeon indicated it could become one of the least invasive surgical heart valve replacement options available.